Ding Xi, Zhao Yang, Zhu Chun-Ying, Wu Li-Ping, Wang Yue, Peng Zhao-Yi, Deji Cuomu, Zhao Feng-Yi, Shi Bing-Yin
Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Department of Disease Prevention And Control, Shaanxi Xi'an Electric Power Center Hospital, Xi'an 710000, China.
Endocr J. 2021 Sep 28;68(9):1043-1056. doi: 10.1507/endocrj.EJ20-0796. Epub 2021 Apr 21.
The association between subclinical hypothyroidism (SCH) and metabolic syndrome (MetS) has been widely discussed. This study aimed to conduct an update and comprehensive meta-analysis to reveal the risk of MetS and its components in SCH. PubMed, Embase and ISI Web of Knowledge were searched to identify relevant studies through February 20, 2020. Review Manager 5.3 and Stata 14.0 were used to conduct the meta-analysis. Both fixed-effects and random-effects models were used. In total, 18 articles (19 studies) incorporating 79,727 participants were included. The pooled OR for MetS comparing subjects with SCH with euthyroid subjects was 1.28 (95% CI: 1.19 to 1.39, p = 0.04, I = 40%). Subgroup analysis results showed significant associations of SCH and MetS in the adult subgroup (OR = 1.28, 95% CI: 1.18-1.40), Asian population subgroup (OR = 1.30, 95% CI: 1.19-1.42) and cross-sectional study design subgroup (OR = 1.31, 95% CI: 1.16-1.47). Significant associations of SCH and MetS also existed in all MetS definition criteria subgroups except the Chinese Diabetes Society (CDS) subgroup. SCH was correlated with MetS and was not affected by the subgroup analysis stratified by the proportion of females in the total population, the TSH cutoff value in SCH diagnostic criteria, or the adjustment for confounding factors. SCH was identified to be associated with an increased risk of obesity, hypertension, high triglyceride (TG) levels and low high-density lipoprotein cholesterol (HDL-C) levels. In conclusion, SCH is significantly associated with an increased risk of MetS and four out of five components of MetS.
亚临床甲状腺功能减退(SCH)与代谢综合征(MetS)之间的关联已得到广泛讨论。本研究旨在进行更新的综合荟萃分析,以揭示SCH中MetS及其组成成分的风险。通过检索PubMed、Embase和ISI Web of Knowledge,以识别截至2020年2月20日的相关研究。使用Review Manager 5.3和Stata 14.0进行荟萃分析。同时采用固定效应模型和随机效应模型。总共纳入了18篇文章(19项研究),涉及79727名参与者。比较SCH患者与甲状腺功能正常患者时,MetS的合并比值比(OR)为1.28(95%置信区间:1.19至1.39,p = 0.04,I² = 40%)。亚组分析结果显示,在成人亚组(OR = 1.28,95%置信区间:1.18 - 1.40)、亚洲人群亚组(OR = 1.30,95%置信区间:1.19 - 1.42)和横断面研究设计亚组(OR = 1.31,95%置信区间:1.16 - 1.47)中,SCH与MetS存在显著关联。除中国糖尿病学会(CDS)亚组外,在所有MetS定义标准亚组中,SCH与MetS也存在显著关联。SCH与MetS相关,且不受总体人群中女性比例、SCH诊断标准中的促甲状腺激素(TSH)临界值或混杂因素调整所分层的亚组分析影响。已确定SCH与肥胖、高血压、高甘油三酯(TG)水平和低高密度脂蛋白胆固醇(HDL-C)水平风险增加相关。总之,SCH与MetS风险增加以及MetS的五个组成成分中的四个显著相关。